An epidermoid cyst in an intrapancreatic accessory spleen is a rare lesion. Despite advances in radiologic techniques, in most cases it has been diagnosed preoperatively as a possible pancreatic neoplasm.
Case presentation
Herein, we present a 63-year-old Caucasian woman, diagnosed preoperatively with enhanced-contrast abdominal computed tomography, as having a potential cystic tumor in the tail of the pancreas. The patient underwent a distal pancreatectomy and splenectomy, and the histological examination revealed the presence of an epidermoid cyst of an accessory intrapancreatic spleen.
Conclusions
Familiarity with the imaging features, the clinical presentation and the location of the cyst are important to consider if this rare entity is to be included in the differential diagnosis of cystic neoplasms of the pancreas.
The online version of this article (doi:10.1186/1477-7819-12-92) contains supplementary material, which is available to authorized users.
Competing interests
All authors have made substantive contributions to the study, and are in agreement with the conclusions of the study. Furthermore, there are no financial competing interests.
Authors’ contributions
NZ and NM wrote the paper. PF carried out the histological and immunohistochemical studies of the surgical specimens. AM, PP and AL were involved in the preoperative, intraoperative and postoperative management of the patient. AM is the head of the Third Department of Surgery. All authors read and approved the final manuscript.
Abkürzungen
AS
accessory spleen
CA
carbohydrate antigen
CEA
carcinoembryonic antigen
CT
computed tomography
EC
epidermoid cyst
ECIPAS
epidermoid cyst in intrapancreatic accessory spleen
The presence of an accessory spleen (AS) at autopsy is estimated to be about 10%, almost 20% of which are found in or attached to the tail of the pancreas[1, 2]. Epidermoid cysts (ECs) account for 10% of benign non-parasitic cysts of the spleen[3]. However, the presence of an EC in an AS is very rare, with 33 cases of ECs found in an intrapancreatic (IP) AS[4‐36], and only one in an AS located in the greater omentum[3].
Herein, we report on a case of an epidermoid cyst in intrapancreatic accessory spleen (ECIPAS), and make a comprehensive review of the literature.
Anzeige
Case presentation
A 63-year-old Caucasian woman was admitted to our hospital with a one-week history of nausea and vomiting after meals. Her medical history included surgery for a peptic ulcer at the age of 48 years. Physical examination was essentially unremarkable. Laboratory data showed normal values. Enhanced-contrast abdominal computed tomography (CT) revealed a mass lesion with solid and cystic components detected in the tail of the pancreas (Figure 1). As concerns serum tumor markers, carbohydrate antigen (CA) 19-9 levels had increased to 222 U/ml (reference range 0 to 27 U/ml). Because a malignant tumor of the pancreas was suspected, the patient underwent a distal pancreatectomy and splenectomy.
×
The cyst measured 12.6 cm at its greatest diameter (Figure 2), and contained a brownish serous composition fluid. No hair or skin appendages were found. Biochemical analysis of the cystic fluid revealed a markedly high level of CA 19-9 (5,000 U/mL) and a moderate elevation of CEA (180.4 ng/ml). Microscopically, the cyst was lined with multilayered (two to five layers thick) flattened epithelium, reminiscent of squamous epithelium above a red pulp splenic parenchyma (Figure 3a). Immunohistochemistry showed that the epithelial cells were positive for keratins AE1/AE3 (Figure 3b), CA 19-9 (Figure 3c) and pCEA (Figure 3d) and negative for vimentin, calretinin and thrombomodulin. Basal epithelial cells where focally reactive with antibodies against D2-40 (Figure 3e) and HBME-1 (Figure 3f). The pathological diagnosis indicated a true epithelial cyst of IPAS.
×
×
Postoperatively, CA 19-9 serum decreased to normal levels after one and a half months. One year later, the patient remains in good health.
Discussion
In 1980, Davidson et al.[4] reported the first case of ECIPAS; and since then 33 articles and 36 patients have been reported in the English language literature (Table 1), suggesting the rarity of the disease. However, the exact incidence of ECIPAS is difficult to determine as over 50% of the cases were incidentally detected[8, 9, 12, 14, 15, 18, 19, 22‐24],[26, 27, 30, 32, 34]. The mean age of the patients was 46.1 years (range 12 to 70 years), with a female preponderance (58.3%)[6, 7, 10‐13, 16, 17, 19‐21, 24‐26, 28],[31, 33, 34, 36]. It is noteworthy that the majority of patients were of Asian origin (28/36 patients, 77.7%), suggesting possibly the presence of a racial factor[26, 27].
Table 1
List of all published cases of epidermoid cyst in intrapancreatic accessory spleen (ECIPAS) in the English language literature
WL: weight loss, NI: no information, DP: distal pancreatectomy, SPL: splenctomy, RLQ: Right lower quadrant, MCN: Mucinous neoplasm, LUQ: Left upper quadrant, PNET: Pancreatic neuroendocrine tumor.
Anzeige
The precise histogenesis of an ECIPAS is not well understood. In summarizing the results of the literature, three main theories have been proposed. The first is based on similar studies of the histogenesis of ECs in the normal spleen suggesting an invagination of capsular mesothelium with subsequent cystic formation and metaplastic changes[37, 38]. The second, based on the presence of keratokine profile of a splenic cyst advocated that ECs are of teratomatous derivation or from inclusion of fetal squamous epithelium[39]. The third, based on immunohistochemical findings, suggests that an ECIPAS may derive either from an aberrant embryonic inclusion of the pancreatic duct epithelium[6], or from a protrusion of a pancreatic duct into an IPAS[11]. The later is questionable as macroscopically, Yokomizo et al.[18] and Iwasaki et al.[31] by using retrograde pancreatography, and Urakami et al.[32] by using magnetic resonance cholangiopancreatography, found no relationship between the pancreatic duct and the ECIPAS.
The histological findings of an ECIPAS in most cases demonstrate a unilocular or multilocular cyst lined by stratified squamous epithelium, keratinizing or not, and surrounded by normal splenic tissue[4‐17, 19‐23, 26‐29, 32‐34]. No skin appendages have been identified[4‐34]. Immunohistochemical examinations of lining epithelium demonstrate positivity for CA 19-9[6, 10‐12, 15, 18, 20, 22, 24, 27],[30] and CEA[10‐12, 15, 22, 24, 29]. Our immunohistochemical findings were found to accord with those of the above mentioned studies, showing positivity for anti-CA 19-9 and anti-pCEA antibodies. According to Higaki et al.[10], the high levels of CA 19-9 and/or CEA in the serum and in the cystic fluid[11] are produced by the squamous epithelium lining and released into the circulation due to trauma or increased intracystic pressure. The fall in levels noted after surgery further supports this suggestion[10].
The clinical presentation is not characteristic. Symptoms include epigastric pain, abdominal pain/discomfort, nausea, vomiting, and weight loss. However, in the reviewed cases, twenty patients (58.3%) (Table 1) were asymptomatic and were identified during radiological examinations for other reasons.
At present, U/S, CT-scan, and MRI are the main imaging tools to detect the lesion. The diameter of the cyst in the reported cases varied from 1.4 to 15 cm (mean 3.89 cm, 2.66 SD). On MRI, the cystic component was hypointense on T1-weighted images and hyperintense on T2-weighted images[13, 18‐20, 23, 29, 33]. However, in most cases a diagnosis of a mucinous cystadenoma[4, 15, 18‐21, 26, 27, 30, 31], cystadenocarcinoma[4, 16, 18, 20], pseudocyst[4, 5, 17], or a potential malignant tumor[25, 34] was suspected. Interestingly, in two cases[23, 29], an ECIPAS was diagnosed in one[23] and strongly suspected in the other[29] based on CT and MRI findings. The radiological signs were related to the homogeneous attenuation of the solid component of the cyst and the adjacent spleen on enhanced CT studies and T1-weighted magnetic resonance images, and on the smooth cystic nature of the inner wall. Itano et al.[23] stated that a relatively adequate splenic mass of AS surrounding the EC is essential for a correct preoperative diagnosis. Additional diagnostic modalities such as endoscopic ultrasonography (EUS), EUS-guided fine needle aspiration of the cystic component, fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET)[31], and EUS- elastography[33] may be used as complementary tools in the diagnosis of an ECIPAS. Recently, a promising diagnostic method was suggested by Motosugi et al.[40], who reported on five subjects as having ECIPAS by using superparamagnetic iron oxide enhanced MRI. Four of them were followed up without surgical intervention.
Although the lesion is considered to be benign and surgery was avoidable[41] Elit et al.[42] reported a squamous cell carcinoma deriving from an EC located in the normal spleen. Taking into account that the lesions of the normal spleen could affect an AS[5], a possible malignant transformation cannot be excluded if the cyst remains unresected. However, no malignancy of an ECIPAS has yet been reported.
Until now, the treatment of ECIPAS consists of surgical removal, either open[4‐28, 30‐32, 36], or laparoscopic[29, 33‐35], with or without splenic preservation. No death has been reported during operation or in the short-term postoperative period.
Conclusions
An ECIPAS is a very rare entity. So far, there are not accurate criteria for the preoperative diagnosis of an ECIPAS, and a definite diagnosis derives from pathological examination after surgical removal. Advances in imaging techniques and familiarity with the radiological findings and clinical characteristics of ECIPAS may help determine the correct management of this lesion.
Consent
Written informed consent was obtained from the patient for publication of this case and for the accompanying images.
Anzeige
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Competing interests
All authors have made substantive contributions to the study, and are in agreement with the conclusions of the study. Furthermore, there are no financial competing interests.
Authors’ contributions
NZ and NM wrote the paper. PF carried out the histological and immunohistochemical studies of the surgical specimens. AM, PP and AL were involved in the preoperative, intraoperative and postoperative management of the patient. AM is the head of the Third Department of Surgery. All authors read and approved the final manuscript.
Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.
Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.